2 Sprecher E. What do rare and common have in common? Br J Dermatol. 2022;187(3):279-80. Abgerufen am 18.09.2022. Adaptation mit freundlicher Genehmigung von Oxford University Press.
3 Ferreira CR. The burden of rare diseases. Am J Med Genet A. 2019;179(6):885–92.
4 Nguengang Wakap S, Lambert DM, Olry A, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. European Journal of Human Genetics. 2020;28(2):165–73.
5 Röcken M, Racke M, Shevach EM. IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimmune disease. Immunology Today. 1996;17(5):225–31.
6 Tanaka A, Arita K, Lai-Cheong JE, Palisson F, Hide M, McGrath JA. New insight into mechanisms of pruritus from molecular studies on familial primary localized cutaneous amyloidosis. Br J Dermatol. 2009;161(6):1217–24.
7 Kabashima K, Irie H. Interleukin-31 as a Clinical Target for Pruritus Treatment. Front Med (Lausanne). 2021;8:638325.
8 Ständer S, Yosipovitch G, Legat FJ, et al. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis. N Engl J Med. 2020;382(8):706–16.
9 Shehadeh W, Sarig O, Bar J, Sprecher E, Samuelov L. Treatment of epidermolysis bullosa pruriginosa-associated pruritus with dupilumab. Br J Dermatol. 2020;182(6):1495–7.
10 Conrad C, Gilliet M. Psoriasis: from Pathogenesis to Targeted Therapies. Clin Rev Allergy Immunol. 2018;54(1):102–13.
11 Baum P, Visvanathan S, Garcet S, et al. Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis. J Allergy Clin Immunol. 2022;149(4):1402–12.
12 Choon SE, Lebwohl MG, Marrakchi S, et al. Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare. BMJ Open. 2021;11(3):e043666.
13 Kibbi N, Rajan N. Reading through genetic ‘stop signs’: a therapeutic strategy in genetic skin disease. Br J Dermatol. 2020;183(1):11.
14 Greco C, Leclerc-Mercier S, Chaumon S, et al. Use of Epidermal Growth Factor Receptor Inhibitor Erlotinib to Treat Palmoplantar Keratoderma in Patients With Olmsted Syndrome Caused by TRPV3 Mutations. JAMA Dermatol. 2020;156(2):191–5.
15 Zhang A, Duchatelet S, Lakdawala N, et al. Targeted Inhibition of the Epidermal Growth Factor Receptor and Mammalian Target of Rapamycin Signaling Pathways in Olmsted Syndrome. JAMA Dermatol. 2020;156(2):196–200.
16 Leuenberger M, Fischer L, Mylonas A, et al. Papillon-Lefevre syndrome treated by acitretin: case report and cytokine profile. J Eur Acad Dermatol Venereol. 2022;36(3):e235–e238.
17 Drislane C, Irvine AD. The role of filaggrin in atopic dermatitis and allergic disease. Ann Allergy Asthma Immunol. 2020;124(1):36–43.
18 Wilson M, Johnson RP, Senft SC, Pan EY, Krakowski AC. Advanced basal cell carcinoma: What dermatologists need to know about treatment. J Am Acad Dermatol. 2022;86(6s):S14–s24.
19 Swartling C, Vahlquist A. Treatment of pachyonychia congenita with plantar injections of botulinum toxin. Br J Dermatol. 2006;154(4):763–5.
20 Paller AS. Profiling Immune Expression to Consider Repurposing Therapeutics for the Ichthyoses. J Invest Dermatol. 2019;139(3):535–40.
21 Rheinwald JG, Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell. 1975;6(3):331–43.
22 Rheinwald JG, Green H. Epidermal growth factor and the multiplication of cultured human epidermal keratinocytes. Nature. 1977;265(5593):421–4.
23 Kueckelhaus M, Rothoeft T, De Rosa L, et al. Transgenic Epidermal Cultures for Junctional Epidermolysis Bullosa – 5-Year Outcomes. N EnglJ Med. 2021;385(24):2264–70.
24 Gurevich I, Agarwal P, Zhang P, et al. In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial. Nat Med. 2022;28(4):780–8.